Posthepatectomy HBV reactivation in hepatitis B-Related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels

Annals of Surgery

Volumn 257, Issue 3, 2013, Pages 490-505

  Huang, Gang ^a   Lai, Eric C H ^a,b   Lau, Wan Yee ^a,b   Zhou, Wei Ping ^a   Shen, Feng ^a   Pan, Ze Ya ^a   Fu, Si Yuan ^a   Wu, Meng Chao ^a  

^a EASTERN HEPATOBILIARY SURGERY HOSPITAL   (China)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Antiviral therapy; HBV reactivation; hepatectomy; hepatitis B; hepatocellular carcinoma

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B VIRUS DNA; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD TRANSFUSION; CANCER SIZE; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIMIT OF QUANTITATION; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PORTAL VEIN THROMBOSIS; PREOPERATIVE CARE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS REACTIVATION;

CARCINOMA, HEPATOCELLULAR; CHINA; DISEASE-FREE SURVIVAL; DNA, VIRAL; FEMALE; HEPATECTOMY; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84873993439     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318262b218     Document Type: Article

References (56)

1. Gomaa AI, Khan SA, ToledanoMB, et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300-4308.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
3. Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol. 2003;39:S59-S63.
4. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serumhepatitis B virus DNA level. JAMA. 2006;295:65-73.
5. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351: 1521-1531.
6. Chu CM, Chen YC, Tai DI, et al. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin Gastroenterol Hepatol. 2010;8:535-540.
7. Lise M, Bacchetti S, Da Pian P, et al. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. Cancer. 1998;82:1028-1036.
8. Chen MF, Hwang TL, Jeng LB, et al. Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg. 1994;129:738-742.
9. Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373-382.
10. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500-507.
11. Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007;141:330-339.
12. Nanashima A, Tanaka K, Yamaguchi H, et al. Fibrosis and inflammatory activity in noncancerous tissue and mitotic index of cancer tissue in patients with hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection. Dig Dis Sci. 2003;48:1517-1522.
13. Hung IF, Poon RT, Lai CL, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008;103:1663-1673.
14. Kusumoto S, Tanaka Y, Mizokami M, et al. Clinical significance of hepatitis B virus (HBV)-DNA monitoring to detect HBV reactivation after systemic chemotherapy. J Clin Oncol. 2011;29:e100; author reply e101.
15. Alvarez-Suarez B, de-la-Revilla-Negro J, Ruiz-Antoran B, et al. Hepatitis B reactivation and current clinical impact. Rev Esp Enferm Dig. 2010;102:542-552.
16. Hogan BV, PeterMB, Shenoy HG, et al. Surgery induced immunosuppression. Surgeon. 2011;9:38-43.
17. Kubo S, Nishiguchi S, Hamba H, et al. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann Surg. 2001;233:139-145.
18. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
19. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
20. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62: 299-307.
21. Liao CA, Lee CM, Wu HC, et al. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol. 2002;116:166-169.
22. Lim LL, Wai CT, Lee YM, et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther. 2002;16:1939-1944.
23. Markovic S, Drozina G, Vovk M, et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology. 1999;46:2925-2930.
24. Leaw SJ, Yen CJ, Huang WT, et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83:270-275.
25. Dai MS, Wu PF, Shyu RY, et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004;24:540-546.
26. Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:553-561.
27. Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004;41:427-435.
28. Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol. 2004;15:1661-1666.
29. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702-709.
30. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927-934.
31. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99:2324-2330.
32. Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat. 2004;11:55-59.
33. Mannick JA, Rodrick ML, Lederer JA. The immunologic response to injury. J Am Coll Surg. 2001;193:237-244.
34. Dietz A, Heimlich F, Daniel V, et al. Immunomodulating effects of surgical intervention in tumors of the head and neck. Otolaryngol Head Neck Surg. 2000;123:132-139.
35. Delogu G, Moretti S, Antonucci A, et al. Apoptosis and surgical trauma: dysregulated expression of death and survival factors on peripheral lymphocytes. Arch Surg. 2000;135:1141-1147.
36. Sietses C, Beelen RH, Meijer S, et al. Immunological consequences of laparoscopic surgery, speculations on the cause and clinical implications. Langenbecks Arch Surg 1999;384:250-258.
37. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233-240.
38. Poon RT, Fan ST, Lo CM, et al. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol. 2000;18:1094-1101.
39. Sonoyama T, Ochiai T, Hironaka T, et al. Predictors of postoperative diffuse intrahepatic recurrence of hepatocellular carcinoma. Hepatogastroenterology. 2003;50:1078-1084.
40. Nagasue N, Ono T, Yamanoi A, et al. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg. 2001;88:515-522.
41. Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007;47:684-690.
42. Yuen MF, Tanaka Y, Shinkai N, et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut. 2008;57:98-102.
43. Ohata K, Hamasaki K, Toriyama K, et al. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2004;19:670-675.
44. Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51:890-897.
45. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686.
46. Kubo S, Hirohashi K, Tanaka H, et al. Virologic and biochemical changes and prognosis after liver resection for hepatitis B virus-related hepatocellular carcinoma. Dig Surg. 2001;18:26-33.
47. Qu LS, Jin F, Huang XW, et al. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J Gastrointest Surg. 2010;14:1111-1120.
48. An HJ, Jang JW, Bae SH, et al. Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1876-1882.
49. Hoshida Y. Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence. J Hepatol. 2009;51:842-844.
50. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
51. Cheung YS, Chan HL,Wong J, et al. Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy. Asian J Surg. 2008;31:41-49.
52. Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol. 2007;13:74-81.
53. Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res. 2003;60:145-150.
54. Pan J, Clayton M, Feitelson MA. Hepatitis B virus X antigen promotes transforming growth factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and down-regulation of alpha2-macroglobulin. J Gen Virol. 2004;85:275-282.
55. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742-1749.
56. Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54:1597-1603.